In general, further efforts to stratify patients according to their immunological characteristics are essential, especially since none of the proposed classifications are clinically established, and the evaluation of tumoral PD-1/PD-L1 status alone has not emerged to be robust in HCC [11,141,142]. This evidence concerns the gene CD274 and hepatocellular carcinoma.